Pacritinib in real-world settings for myelofibrosis
Part of Blood & lymphatic clinical trials.
This study looks at how well pacritinib works in everyday medical practice for people with myelofibrosis, a type of bone marrow disorder. It helps us understand the benefits and risks of this treatment for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with myelofibrosis.
- Your platelet count was at least 50,000 per microliter when you started pacritinib.
- You have taken pacritinib for at least one month, or if you stopped earlier, you have been followed for at least 6 months.
- If your blood was tested for blasts (immature cells), they were under 10% before starting pacritinib.
- You have not had acute myeloid leukemia, and your doctor is not concerned you have developed a more aggressive form of the disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
This study tests a new combination of two drugs, tagraxofusp and pacritinib, for people with myelofibrosis who have already tried a JAK inhibitor without enough benefit or who couldn't take one. The goal is to see if the combination can shrink the spleen and improve symptoms.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This study looks at how well momelotinib works in people with myelofibrosis who have an enlarged spleen. It checks the drug's effects in everyday medical practice, not in a strictly controlled lab setting.
This trial tests a drug called pacritinib for people with CMML. It's for those who haven't had JAK inhibitor therapy before and may have had only one cycle of other treatments.
This trial tests two new medicines, selinexor and pacritinib, for people with myelofibrosis who have low blood counts and have not yet tried JAK inhibitor therapy. The goal is to see if this combination helps reduce spleen size and improve blood counts.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.